NCT01562808

Completed

Change in Brain Metabolism and Cognitive Function by Aripipr...

Seoul National University Hospital Source

Compare

Other study identifiers

Sponsor study identifier

A070001

Study Type

interventional

Actual enrollment (reported)

15

Locations

1 country

Sites

1

Timeline

Study Start

January 2009

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

May 2010

Actual (reported)

Study Completion

January 2012

Actual (reported)

Brief Summary

Dopamine receptor occupancy and brain metabolism were measured using positron emission tomography after the administration of aripiprazole. Working memory performance was also measured using N-back task. The investigators explored the relationship between changes in brain metabolism and working memory performance.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 15 participants
Study completion date: January 2012
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
January 2009
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
May 2010
Actual (reported)
Study Completion
January 2012
Actual (reported)
First Submitted
March 22, 2012
Actual (reported)
First Posted
March 26, 2012
Actual (reported)

Last Updated: March 26, 2012
Status Verified: March 2012
Last Update Submitted: March 23, 2012

Conditions

Antipsychotics Brain Metabolism Cognition Dopamine Receptor Occupancy

Outcome Measures

Primary Outcomes (1)

Reaction time of correct response in N-back task
48 hrs after the administration of aripiprazole

Interventions

AripiprazoleDrug

single oral administration of aripiprazole

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age19 Years - 30 Years

Sexmale

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

healthy volunteers
right-handed

You may not qualify if:

Sponsors & Collaborators

Seoul National University Hospital
Otherlead

Study Sites (1)

Seoul National University Hospital

Seoul, 110-744, South Korea

MeSH Terms

Interventions

Aripiprazole

Intervention Hierarchy (Ancestors)

PiperazinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsQuinolonesQuinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

Jun Soo Kwon, M.D., Ph.D.
Seoul National University Hospital
PRINCIPAL INVESTIGATOR

Enrollment

15 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NA
Masking: SINGLE
Who Masked: PARTICIPANT
Purpose: BASIC SCIENCE
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Professor

Study Record Dates

First Submitted

March 22, 2012

First Posted

March 26, 2012

Study Start

January 2009

Date type not reported

This date has not been verified as actual or estimated.

NCT00211380

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)

Not ApplicableTerminated

NCT01338298

Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia

Not ApplicableCompleted

NCT00374348

Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)

Not ApplicableCompleted

NCT00567099

Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole

Not ApplicableUnknown

NCT02013232

Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia

Not ApplicableUnknown

NCT00282139

Aripiprazole in the Treatment of Tourette's Syndrome

Not ApplicableTerminated

any significant abnormality on routine lab
any psychiatric disease

Contact the study team to confirm eligibility.

Primary Completion

May 2010

Actual (reported)

Study Completion

January 2012

Actual (reported)

Last Updated

March 26, 2012

Record last verified: 2012-03

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT01562808
Data provider: ClinicalTrials.gov
Source updated: 2012-03-26
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:40:51 UTC

Locations

KR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations